Loading viewer...
investor_presentation
Format: PDF investor_presentation
Albireo Pharma presents its portfolio of bile acid modulators for orphan pediatric liver diseases at the BIO CEO & Investor Conference. The company highlights its lead candidate A4250 in development for Progressive Familial Intrahepatic Cholestasis (PFIC) and chronic cholestasis, along with partnered asset elobixibat.
presentation
investor_presentation
37 Pages
Snow Lake Lithium Ltd.
investor_presentation
Oncolytics